Atorvastatin therapy reduces serum uric acid levels: A meta-analysis of randomized controlled trials

Takagi, Hisato; Umemoto, Takuya

doi:10.1016/j.ijcard.2012.01.092

Cited by 16 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This recommendation is supported by a large epidemiological study finding relative risks of incident gout associated with the current use of calcium channel blockers and losartan of 0.87 (95% CI 0.82 to 0.93) and 0.81 (95% CI 0.70 to 0.94), respectively 175. Finally, the uricosuric property of fenofibrate176 177 and statins has been further documented 178 179…”

Section: Resultsmentioning

confidence: 82%

2016 updated EULAR evidence-based recommendations for the management of gout

et al. 2016

View full text Add to dashboard Cite

BACKGROUND:\ud New drugs and new evidence concerning the use of established treatments have become available since the publication of the first European League Against Rheumatism (EULAR) recommendations for the management of gout, in 2006. This situation has prompted a systematic review and update of the 2006 recommendations.\ud METHODS:\ud \ud The EULAR task force consisted of 15 rheumatologists, 1 radiologist, 2 general practitioners, 1 research fellow, 2 patients and 3 experts in epidemiology/methodology from 12 European countries. A systematic review of the literature concerning all aspects of gout treatments was performed. Subsequently, recommendations were formulated by use of a Delphi consensus approach.\ud RESULTS:\ud \ud Three overarching principles and 11 key recommendations were generated. For the treatment of flare, colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids or a combination are recommended. In patients with frequent flare and contraindications to colchicine, NSAIDs and corticosteroids, an interleukin-1 blocker should be considered. In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at<6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout. Allopurinol is recommended as first-line ULT and its dosage should be adjusted according to renal function. If the SUA target cannot be achieved with allopurinol, then febuxostat, a uricosuric or combining a xanthine oxidase inhibitor with a uricosuric should be considered. For patients with refractory gout, pegloticase is recommended.\ud CONCLUSIONS:\ud These recommendations aim to inform physicians and patients about the non-pharmacological and pharmacological treatments for gout and to provide the best strategies to achieve the predefined urate target to cure the disease

show abstract

Section: Resultsmentioning

confidence: 82%

2016 updated EULAR evidence-based recommendations for the management of gout

et al. 2016

View full text Add to dashboard Cite

show abstract

“…We used Medical Subject Headings (MeSH) and the keywords CKD, RCTs, and all spellings of uric acid-lowering drugs, including allopurinol, benzbromarone, probenecid, sulfinpyrazone, febuxostat, rasburicase, and pegloticase. Although some other agents, such as angiotensin receptor blockers [ 22 ] and statins [ 23 , 24 ], may also reduce the levels of uric acid, the primary effects of these agents would influence the kidney and cardiovascular outcomes. Accordingly, relevant studies on these agents were excluded.…”

Section: Methodsmentioning

confidence: 99%

Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis

Yan

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Background and objectivesThe effects of uric acid-lowering therapy in patients with chronic kidney disease (CKD) remain uncertain. Therefore, we undertook a systematic review and meta-analysis to investigate the effects of uric acid-lowering agents on major clinical outcomes of CKD.Design, setting, participants, and measurementsAccording to the pre-specified protocol that was registered with PROSPERO (No. CRD42016038030), we searched systematically in MEDLINE, EMBASE, and the Cochrane Library for trials up to February 2016. Prospective, randomized, controlled trials assessing the effects of uric acid-lowering agents on cardiovascular and kidney outcomes in patients with CKD were included. Random-effects analytical methods were used.ResultsSixteen eligible trials were identified, providing data for 1,211 patients with CKD, including 146 kidney failure events and 69 cardiovascular events. Uric acid-lowering therapy produced a 55% relative risk (RR) reduction (95% confidence interval [95% CI], 31–64) for kidney failure events (P < 0.001), and a 60% RR reduction (95% CI, 17–62) for cardiovascular events (P < 0.001), but had no significant effect on the risk of all-cause death (RR, 0.86; 95% CI, 0.50–1.46). The mean differences in rate of decline in the estimated glomerular filtration rate (4.10 mL/min/1.73 m2 per year slower in uric acid-lowering therapy recipients, 95% CI, 1.86–6.35) and the standardized mean differences in the change in proteinuria or albuminuria (−0.23 units of standard deviation greater in uric acid-lowering therapy recipients; 95% CI, −0.43 to −0.04) were also statistically significant.ConclusionsUric acid-lowering therapy seemed to improve kidney outcomes and reduce the risk of cardiovascular events in adults with CKD.

show abstract

“…Recent studies indicate that statins can influence arterial wall stiffness in various ways. The lipid-independent effects of statins have been hypothesized to be due to their pleiotropic effects on vessel wall [6,7] as well as anti-inflammatory [8,9], antioxidant [10,11], anti-thrombotic [12] and hypouricaemic A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 5 [13] . Statins can stabilize atherosclerotic plaques which might have effect on arterial stiffness because of a rapid reduction of lipid vascular contents.…”

Section: Introductionmentioning

confidence: 99%